14540001 Phase I dose escalation BI 765049 in patients with malignant solid tumors expressing B7H6

• Research type

  Research Study

• Full title

  A first-in-human Phase I, non-randomized, open-label, multicenter dose escalation trial of BI 765049 and BI 765049 + ezabenlimab administered by parenteral administration(s) in patients with malignant solid tumors expressing B7-H6

• IRAS ID

  1007545

• Contact name

  Shan Lim

• Contact email

  shan.lim@boehringer-ingelheim.com

• Sponsor organisation

  Boehringer Ingelheim International GmbH

• Clinicaltrials.gov Identifier

  NCT04752215

• Research summary

  A first-in-human study evaluating different doses of BI 765049 when given alone and when given with ezabenlimab to patients with advanced solid tumors expressing the protein B7-H6 on the cell surface.

• REC name

  London - City & East Research Ethics Committee

• REC reference

  24/LO/0343

• Date of REC Opinion

  19 Jun 2024

• REC opinion

  Further Information Favourable Opinion